1. Home
  2. TMHC vs RYTM Comparison

TMHC vs RYTM Comparison

Compare TMHC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taylor Morrison Home Corporation

TMHC

Taylor Morrison Home Corporation

HOLD

Current Price

$71.46

Market Cap

5.5B

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$87.87

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMHC
RYTM
Founded
1936
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.8B
IPO Year
2012
2017

Fundamental Metrics

Financial Performance
Metric
TMHC
RYTM
Price
$71.46
$87.87
Analyst Decision
Buy
Strong Buy
Analyst Count
7
14
Target Price
$71.71
$131.14
AVG Volume (30 Days)
2.8M
538.3K
Earning Date
04-22-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.34
EPS
1.01
N/A
Revenue
$4,762,059,000.00
N/A
Revenue This Year
N/A
$55.34
Revenue Next Year
$8.96
$86.06
P/E Ratio
$70.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.15
$60.71
52 Week High
$72.27
$122.20

Technical Indicators

Market Signals
Indicator
TMHC
RYTM
Relative Strength Index (RSI) 76.26 48.70
Support Level $56.84 $87.19
Resistance Level $72.27 $92.51
Average True Range (ATR) 1.04 3.44
MACD 1.70 -0.48
Stochastic Oscillator 98.13 46.51

Price Performance

Historical Comparison
TMHC
RYTM

About TMHC Taylor Morrison Home Corporation

Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: